Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in Taiwan

Journal of the Formosan Medical Association

Volumn 108, Issue 5, 2009, Pages 402-408

  Chang, Chin Feng ^a,b   Yang, Wei Shiung ^a,b   Su, Yi Ning ^a,b   Wu, I Ling ^a,b   Chang, Tien Chun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Human; Multiple endocrine neoplasia type 2A; Multiple endocrine neoplasia type 2B; Mutation; RET protein; Thyroid neoplasms

Indexed keywords

GENOMIC DNA; PROTEIN RET;

AGED; ARTICLE; CODON; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; EXON; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GERIATRIC PATIENT; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NEUROFIBROMATOSIS; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SIPPLE SYNDROME; TAIWAN; THYROID MEDULLARY CARCINOMA;

EID: 67649577224     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60084-X     Document Type: Article

References (44)

1. Bachelot A, Lombardo F, Baudin E, et al. Inheritable forms of medullary thyroid carcinoma. Biochimie 2002;84:61-66 (Pubitemid 34477093)
2. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005;15:531-544 (Pubitemid 40993726)
3. Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med 2004;24:49-83. (Pubitemid 38638109)
4. Leboulleux S, Baudin E, Travagli JP, et al. Medullary thyroid carcinoma. Clin Endocrinol 2004;61:299-310.
5. Carney JA. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol 2005;29:254-274 (Pubitemid 40170645)
6. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Meta 2001;86:5658-5671 (Pubitemid 33152604)
7. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2005;17:7-12. (Pubitemid 40179904)
8. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005;16:441-467 (Pubitemid 41022013)
9. Santoro M, Melillo RM, Carlomagno F, et al. Minireview: RET: normal and abnormal functions. Endocrinology 2004;145:5448-5451 (Pubitemid 39564582)
10. Alberti L, Carniti C, Miranda C, et al. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 2003;195:168-186 (Pubitemid 36384291)
11. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525 (Pubitemid 37255037)
12. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000;37:817-827 (Pubitemid 30843789)
13. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004;204:197-211.
14. Kodama Y, Asai N, Kawai K, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 2005;96:143-148 (Pubitemid 40575914)
15. Jain S, Watson MA, DeBenedetti MK, et al. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 2004;64:3907-3913 (Pubitemid 38697303)
16. Blank RD, Sklar CA, Dimich AB, et al. Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds. Cancer 1996;78:1996-2003. (Pubitemid 26360585)
17. Huang CN, Wu SL, Chang TC, et al. RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma. J Formos Med Assoc 1998;97:541-546 (Pubitemid 28414524)
18. Wu SL, Chang TC, Huang CN, et al. Germline RET proto-oncogene mutations in two Taiwanese families with multiple endocrine neoplasia type 2A. J Formos Med Assoc 1998;97:614-618 (Pubitemid 28467651)
19. Chang TJ, Wu SL, Chang TC, et al. De novo RET proto-oncogene mutation in a patient with multiple endocrine neoplasia type 2B. J Formos Med Assoc 1999;98:692-697
20. Erdogan MF, Gursoy A, Ozgen G, et al. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 2005;28:806-809 (Pubitemid 43162835)
21. Da Silva AM, Maciel RM, Da Silva MR, et al. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:5438-5443 (Pubitemid 37452751)
22. Komminoth P, Roth J, Muletta-Feurer S, et al. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996;81:2041-2046 (Pubitemid 26175924)
23. Lee MJ, Su YN, You HL, et al. Identification of forty-five novel and twenty-three known NF1 mutations in Chinese patients with neurofibromatosis type 1. Hum Mutat 2006;27:832.
24. Cote GJ, Gagel RF. Lessons learned from the management of a rare genetic cancer. N Engl J Med 2003;349:1566-1568 (Pubitemid 37255043)
25. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113 (Pubitemid 41317433)
26. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257:50-59 (Pubitemid 40129126)
27. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg 2007;42:326-332 (Pubitemid 46161553)
28. Wiench M, Wygoda Z, Gubala E, et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients.; Clin Oncol 2001;19:1374-1380 (Pubitemid 32202543)
29. Lesueur F, Cebrian A, Robledo M, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006;66:1177-1180 (Pubitemid 43165988)
30. Boikos SA, Stratakis CA. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Histol Histopathol 2008;23:109-116
31. Zhou Y, Zhao Y, Cui B, et al. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. Clin Endocrinol 2007;67:570-576 (Pubitemid 47416316)
32. Kim IJ, Kang HC, Park JH, et al. RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes. Clin Cancer Res 2002;8:457-463 (Pubitemid 34193965)
33. Chung YJ, Kim HH, Kim HJ, et al. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Thyroid 2004;14:813-818 (Pubitemid 39489005)
34. Bae SJ, Kim DJ, Kim JY, et al. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A. Thyroid 2006;16:609-614 (Pubitemid 44066269)
35. Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol 2006;247:34-40. (Pubitemid 43277705)
36. Machens A, Brauckhoff M, Holzhausen HJR, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005;90:3999-4003. (Pubitemid 41058163)
37. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2 - evaluation of the genotype-phenotype relationship. Arch Surg 2003;138:409-416 (Pubitemid 36417678)
38. van Heurn LWE, Schaap C, Sie G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 1999;34:568-571 (Pubitemid 29183789)
39. Huang SH, Kou MS, Jin YT, et al. Prophylactic total thyroidectomy in an 8-year-old girl with multiple endocrine neoplasia type 2A. J Formos Med Assoc 2001;100:274-276 (Pubitemid 32451963)
40. Uchino S, Noguchi S, Sato M, et al. Presymptomatic detection and treatment of Japanese carriers of the multiple endocrine neoplasia type 2A gene. Surg Today 1999;29:862-867 (Pubitemid 29459537)
41. Kameyama K, Takami H. Medullary thyroid carcinoma: nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002. Endocr J 2004;51:453-456
42. Kameyama K, Okinaga H, Takami H. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother 2004;58:345-347 (Pubitemid 38951066)
43. Huang SM, Tao BL, Tzeng CC, et al. Prenatal molecular diagnosis of RET proto-oncogene mutation in multiple endocrine neoplasia type 2A. J Formos Med Assoc 1997;96:542-544 (Pubitemid 27325965)
44. Martinelli P, Maruotti GM, Pasquali D, et al. Genetic prenatal RET testing and pregnancy management of multiple endocrine neoplasia Type II A (MEN2A): a case report. J Endocrinol Invest 2004;27:357-360 (Pubitemid 38744615)